Skip to content

Research on new imaging technique for personalized breast cancer treatment (BREAST4D)

Clinical evaluation of 4D Breast Imaging for Personalized Breast Cancer Treatment - BREAST4D

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON53871
Enrollment
250
Registered
2022-12-05
Start date
2025-11-04
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer Mamma carcinoma breast cancer

Interventions

4D dynamic contrast enhanced Breast CT

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Women >18 years old - Diagnosis of breast cancer - Treatment not yet initiated

Exclusion criteria

Exclusion criteria: - Suspected or confirmed pregnancy - Women who are breastfeeding - Women who have had bilateral mastectomy - Women who cannot give informed consent - Contra-indication for iodine contrast (i.e., contrast allergy, renal function impairment (GFR

Design outcomes

Primary

MeasureTime frame
Part A: Detection of additional tumor foci and tumor centers in either breast. Part B: The prediction of final outcome at each imaging time point, and identification of the markers that allow for prediction of final outcome.

Secondary

MeasureTime frame
Part A: o The frequency and appropriateness of change in surgical planning. o The identification of imaging biomarkers that characterize tumor molecular profiles at the sub-tumor level. o Determination of local cell density and vascular access to the different tumor regions. o Comparison of the results obtained from the 4D DCE-BCT and DCE-MRI. Part B: Direct comparison of the predictive and classification ability of 4D DCE-BCT and DCE-MRI for therapeutic response to NAT.

Countries

Netherlands

Contacts

Public ContactL.D. Dolman-Mauritz

Radboud Universitair Medisch Centrum

laura.dolman-mauritz@radboudumc.nl0641540272

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jun 11, 2026